Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study

OBJECTIVE: We investigate safety and efficacy in common clinical practice of the combination of carfilzomib and dexamethasone (Kd56) approved for the ENDEAVOR trial for the treatment of relapsed or refractory multiple myeloma. METHODS: We retro‐prospective analyzed 75 patients in three centers in Tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Giudice, Maria Livia, Gozzetti, Alessandro, Antonioli, Elisabetta, Attucci, Irene, Pengue, Ludovica, Cassano Cassano, Raffaella, Ghio, Francesco, Orciuolo, Enrico, Simoncelli, Martina, Bocchia, Monica, Galimberti, Sara, Buda, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544660/
https://www.ncbi.nlm.nih.gov/pubmed/35749094
http://dx.doi.org/10.1111/ejh.13819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544660/
https://www.ncbi.nlm.nih.gov/pubmed/35749094
http://dx.doi.org/10.1111/ejh.13819

Ejemplares similares